February 11, 2012
| Bio-IT World > Bio-IT Briefs


Bio-IT Briefs



Phase Forward announced the availability of WebVDME 6.0, the latest release of the company’s pharmacovigilance and signal management product. The new release includes more tools and features for discovering and investigating signals in greater depth, exploring varied combinations of factors that trigger adverse events and simplifying analysis of safety data. WebVDME is used by pharmaceutical and biotech companies as well as several regulatory agencies, many of which participated in the project as development or testing partners. Read the press release.

Medidata Solutions announced that Orion Corp. has chosen to standardize on Medidata Rave as its global electronic data capture (EDC) management and reporting solution. This year, Orion plans to use Rave for most of the clinical studies throughout Europe. With an ultimate goal of eliminating paper-based clinical processes, Orion expects all of the company’s trials will be managed by Medidata Rave within the next few years. Read the press release.

Genizon BioSciences announced the first closing of its Series D equity financing, in the amount of CDN$10 million. Investors include Pfizer Inc. and existing investor BTF B.V. of Haarlem, The Netherlands, a venture capital fund focused on late stage biotechnology companies. Pfizer's investment in Genizon is related to a license and collaboration agreement announced January 16, 2007. Genizon will use the funds to conduct genome-wide association studies in the Quebec Founder Population and to enhance and commercialize discoveries already generated from previous studies.  Read the press release.

elbion NV, a European specialty pharmaceutical company with a focus on neurology and immunology, today announced it has entered a research and license agreement with Wyeth Pharmaceuticals, a division of Wyeth, around elbion's phosphodiesterase 10 (PDE10) program for CNS disorders with an initial focus on schizophrenia. The agreement includes an upfront payment, milestones and research funding potentially totalling up to $110 million over the life of the agreement. Wyeth will also pay elbion royalties on worldwide annual net sales of products developed under the agreement. Read the press release.

Stratagene Corp. has obtained the last of the four co-exclusive licenses to more than 150 microRNA sequences available from Max Planck Innovation, the technology transfer agency of the Max Planck Society. Under the terms of the agreement, Stratagene will have the right to use the microRNA sequences for the development, manufacture and sale of molecular diagnostic kits. Read the press release.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 
Apply at http://jobs.tessella.com   

oxford nanopore logo 


Early Access Collaborations ManagersClick here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Click to  Apply  

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .